

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Adam, G Examiner: Sitton, Jehanne S.  
Serial No.: 10/608,296 Group Art Unit: 1634  
Filed: June 27, 2003 Docket: SEQ-4031-UT  
Conf. No.: 9001  
Title: DIAGNOSING PREDISPOSITION TO FAT DEPOSITION AND ASSOCIATED CONDITIONS

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication. Applicants also bring to the Examiner's attention the existance of the following co-pending related applications: (1) application no. 10/455,552 filed June 4, 2003 and published January 29, 2004 as US2004-0018533 A1 (Attorney Docket No. SEQ-4030-UT, Examiner Terra C. Gibbs), and (2) application no. 10/607,806 filed June 27, 2003 and published on January 20, 2005 as US2005-

**INFORMATION DISCLOSURE STATEMENT**

Serial No.: 10/608,296

Filing Date: June 27, 2003

Title: Diagnosing Predisposition To Fat Deposition And Associated Conditions

Page 2  
Dkt: SEQ-4031-UT

0014158 A1 (Attorney Docket No. SEQ-4032-UT, Examiner Paul C. Martin).

The documents referenced in the attached Form SB08 were cited in a supplemental search report from the European Patent Office dated September 15, 2006. Therefore, each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The listed documents are being submitted in compliance with 37 CFR § 1.97(c), after the mailing date of the first Office action on the merits, but prior to a final Office action, and Applicants respectfully submit payment of \$180.00.

If any additional fees are due, please contact the undersigned attorney at (858) 623-9470. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date: December 13, 2006

By: /Bruce Grant/

Bruce Grant

Reg. No. 47608

Attorney for Applicants

BioTechnology Law Group

Customer No. 47328

Telephone: (858) 623-9470

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known	
<b>Application Number</b>	10/608,296
<b>Filing Date</b>	June 27, 2003
<b>First Named Inventor</b>	Gail Adam
<b>Group Art Unit</b>	1634
<b>Examiner Name</b>	Sitton, Jehanne S.

Sheet 1 of 1

Attorney Docket No: SEQ-4031-UT

**US PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	56211233	04/15/1997	Johnson et al	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	A2.	EP 0356454	10/20/1988	Bundy and Youngdale		

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A3.	Huggins et al., Gastroenterology, 120(5, sup1):A42 #214 Meeting Abstract	
	A4.	Huggins et al., Gastroenterology, 120(5, sup1):A68 #491 Meeting Abstract	
	A5.	Huggins et al., Am. J. Physiol., 283(5):E994-E1001	
	A6.	Homan et al., J. Lipid Research, 39(6):1197-1209	
	A7.	European Patent Office Supplementary Search Report	

**EXAMINER**

**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant: 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached.